Evidence map›Paper›PMID 25267927›Full record

ArticleNano today2014

Nanomedicine in the Management of Microbial Infection - Overview and Perspectives.

Xi Zhu, Aleksandar F Radovic-Moreno, Jun Wu, Robert Langer, Jinjun Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano today, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Nanoparticles as Alternatives for the Control ofFrontiers in veterinary science · 2021
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xi ZhuBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA ; West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Aleksandar F Radovic-MorenoDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA ; Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USA.
Jun WuBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Robert LangerDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA ; Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USA.
Jinjun ShiBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA ; Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USA.

Funding

The Development of Clinical Grade, Targeted Magnetic NanoparticlesU54CA151884 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MESIROV, JILL P. · 2010 to 2014
$11.3M
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant CancersR00CA160350 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI SHI, JINJUN · 2013 to 2015
$724k
NCI NIH HHS R00 CA160350NCI NIH HHS U54 CA151884
6 · The paper itself

Abstract

For more than 2 billion years, microbes have reigned on our planet, evolving or outlasting many obstacles they have encountered. In the 20

Indexed as

DiagnosisDrug deliveryMedical deviceMicrobial infectionNanomedicineTherapyVaccine

Identifiers

PMID25267927
PMCPMC4175422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.